Navigation Links
Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling

Dr. Bill Poland Will Discuss Best Practices in HCV and HIV Drug-Disease Modeling and Simulation to Support Clinical Drug Development Decision


MOUNTAIN VIEW, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Bill Poland, Ph.D., vice president and lead scientist, Strategic Consulting Services, will speak to members of the pharmaceutical and biotechnology industries via web conference on HCV/HIV drug-disease modeling on Thursday, February 28, 2008, at 1:00 p.m. Eastern Standard Time (10:00 a.m. PST).

Dr. Poland's presentation, entitled "Portable Concepts for HCV and HIV Drug-Disease Modeling and Simulation" will discuss the use and strategic value of quantitative modeling and simulation to design, predict and improve clinical trial outcomes for HCV and HIV drugs. Applied case examples will illustrate that despite important differences between HCV and HIV, such as the potential to cure HCV and faster HCV dynamics, HCV trial outcomes, like those for HIV, can be predicted and improved by model-informed design. More information about this event is available at

"HCV and HIV present special therapeutic challenges to drug development teams, including the emergence of resistance, complex pharmacokinetics, and patient compliance," said Shawn O'Connor, president, CEO and chairman of Pharsight. "To support planning and quantitative decision-making for antiviral development, it is important to leverage synergies wherever possible in the complexities of viral dynamics modeling. HIV and HCV drug development programs can benefit from Pharsight's predictive modeling methods and extensive knowledge of the competitive treatment landscape. Model-based approaches can lead to enhanced clinical trial designs and in developing strategies to optimize tradeoffs such as that between patient compliance and dosing regimen, as well as inform better clinical program investment decisions."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA and Pharsight Continue to Collaborate Under CRADA
2. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
3. Pharsight Achieves $7.3 Million in Quarterly Revenue
4. Pharsight Expands Global Consulting Services Teams
5. Pharsight to Host European Software Conference
6. Pharsight Files Application for Nasdaq Capital Market Listing
7. FairWarning to Host Webinar Featuring HIMSS Chairman and Healthcare Executive from PricewaterhouseCoopers on Electronic Health Record Privacy and Compliance Challenges
8. Portico Systems Offers Webinar Series to Share Provider Network Management Best Practices
9. Uncover Key Competitive Intelligence Insights in Webinars Hosted by Best Practices
10. GenOdyssee Receives Notice of Allowance from U.S. Patent Office for Improved Interferon-Alpha Aimed at Hepatitis C
11. Grapefruit compound may help combat hepatitis C infection
Post Your Comments:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
Breaking Medicine Technology: